Jeddah, Saudi Arabia – Jamjoom Pharmaceuticals Factory Company (Jamjoom Pharma), a leading pharmaceutical company in the Middle East and Africa, today announced a significant strategic commercialization agreement with Bio-Thera Solutions, Ltd. (688177:SH), a global biopharmaceutical company. The partnership secures the exclusive rights for Jamjoom Pharma to commercialize BAT2306, a proposed biosimilar to Novartis’s Cosentyx®️ (secukinumab), across the Middle East and North Africa (MENA) region.
This collaboration marks a major step forward in expanding access to advanced biologic therapies for patients in the MENA region. Under the terms of the agreement, Jamjoom Pharma will be responsible for all regulatory submissions, market access, and commercialization activities for BAT2306. Bio-Thera Solutions will maintain responsibility for product development and global manufacturing from its state-of-the-art facilities in Guangzhou, China.
Tarek Hosni, Chief Executive Officer of Jamjoom Pharma, expressed his enthusiasm for the partnership. “This collaboration is a strategic milestone for Jamjoom Pharma and a testament to our mission of broadening access to advanced biologics in the MENA region,” he said. “By joining forces with Bio-Thera, we are combining world-class biosimilar development with Jamjoom’s deep regional expertise, strong commercial capabilities, and commitment to delivering high-quality, affordable therapies. This agreement strengthens our leadership in the biopharmaceutical sector and reinforces our role as a trusted partner in improving patient outcomes.”
Bert Thomas, Senior Vice President of Business Development at Bio-Thera Solutions, highlighted the shared vision of the two companies. “Bio-Thera is committed to bringing affordable medicines to patients in need around the world,” he stated. “Partnering with Jamjoom Pharma to bring BAT2306 to patients in the MENA region is a demonstration of that commitment. We are proud to partner with Jamjoom Pharma and look forward to a successful collaboration.”
This agreement leverages the strengths of both companies to address the growing demand for accessible, high-quality treatments for inflammatory diseases in the MENA market. The partnership between a globally recognized biosimilar developer and a rapidly growing regional pharmaceutical leader is set to create significant value for healthcare systems and patients across the region.
